{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T19:06:20Z","timestamp":1788375980485,"version":"build-2803163510"},"reference-count":244,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Health of the Russian Federation under the Research","award":["125012100524-9"],"award-info":[{"award-number":["125012100524-9"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Multiple myeloma (MM or plasma cell myeloma) is a heterogenous B-cell malignant tumor that typically exhibits a high recurrence rate, resistance to drugs, and molecular diversity of tumor subclones. Given the limited efficacy of standard therapy options, cellular immunotherapy featuring a chimeric antigen receptor (CAR) has proven tangible potential in treatment for relapsed and refractory forms of MM. The rational choice of a tumor target which shows high selectivity, stable expression, and biological significance is key to the successful implementation of CAR therapy. This review has summarized and analyzed data from the literature on biological properties, the features of expression, and the clinical development stages of CAR cell products for MM treatment which target BCMA, GPRC5D, FcRH5, SLAMF7, CD38, CD138, TACI, APRIL, CD19, TNFR2, CD44v6, CD70, NKG2D ligands, etc. Special focus is on strategic approaches to overcoming antigenic escape, such as multi-specific CAR constructs, logical activation sequences, and controlled safety systems. The analysis underscores the need for integrating the molecular selection of targets with cutting-edge bioengineering solutions as a key trend for raising the efficacy, stability, and safety of cellular therapy in the case of MM.<\/jats:p>","DOI":"10.3390\/ijms26136051","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T06:49:38Z","timestamp":1750747778000},"page":"6051","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Targets for CAR Therapy in Multiple Myeloma"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5009-1508","authenticated-orcid":false,"given":"Olga A.","family":"Bezborodova","sequence":"first","affiliation":[{"name":"Moscow Hertsen Research Institute of Oncology\u2014Branch of the National Medical Radiology Research Center, Ministry of Health of the Russian Federation, Moscow 125284, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galina V.","family":"Trunova","sequence":"additional","affiliation":[{"name":"Moscow Hertsen Research Institute of Oncology\u2014Branch of the National Medical Radiology Research Center, Ministry of Health of the Russian Federation, Moscow 125284, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3579-1733","authenticated-orcid":false,"given":"Elena R.","family":"Nemtsova","sequence":"additional","affiliation":[{"name":"Moscow Hertsen Research Institute of Oncology\u2014Branch of the National Medical Radiology Research Center, Ministry of Health of the Russian Federation, Moscow 125284, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0339-2068","authenticated-orcid":false,"given":"Varvara A.","family":"Khokhlova","sequence":"additional","affiliation":[{"name":"Moscow Hertsen Research Institute of Oncology\u2014Branch of the National Medical Radiology Research Center, Ministry of Health of the Russian Federation, Moscow 125284, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia B.","family":"Venediktova","sequence":"additional","affiliation":[{"name":"Moscow Hertsen Research Institute of Oncology\u2014Branch of the National Medical Radiology Research Center, Ministry of Health of the Russian Federation, Moscow 125284, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7159-805X","authenticated-orcid":false,"given":"Natalia B.","family":"Morozova","sequence":"additional","affiliation":[{"name":"Moscow Hertsen Research Institute of Oncology\u2014Branch of the National Medical Radiology Research Center, Ministry of Health of the Russian Federation, Moscow 125284, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9320-1746","authenticated-orcid":false,"given":"Maria S.","family":"Vorontsova","sequence":"additional","affiliation":[{"name":"Moscow Hertsen Research Institute of Oncology\u2014Branch of the National Medical Radiology Research Center, Ministry of Health of the Russian Federation, Moscow 125284, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna D.","family":"Plyutinskaya","sequence":"additional","affiliation":[{"name":"Moscow Hertsen Research Institute of Oncology\u2014Branch of the National Medical Radiology Research Center, Ministry of Health of the Russian Federation, Moscow 125284, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6466-5348","authenticated-orcid":false,"given":"Elena P.","family":"Zharova","sequence":"additional","affiliation":[{"name":"Moscow Hertsen Research Institute of Oncology\u2014Branch of the National Medical Radiology Research Center, Ministry of Health of the Russian Federation, Moscow 125284, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter V.","family":"Shegai","sequence":"additional","affiliation":[{"name":"Moscow Hertsen Research Institute of Oncology\u2014Branch of the National Medical Radiology Research Center, Ministry of Health of the Russian Federation, Moscow 125284, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey D.","family":"Kaprin","sequence":"additional","affiliation":[{"name":"Moscow Hertsen Research Institute of Oncology\u2014Branch of the National Medical Radiology Research Center, Ministry of Health of the Russian Federation, Moscow 125284, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood.2023022499","article-title":"BCMA- or GPRC5D-Targeting Bispecific Antibodies in Multiple Myeloma: Efficacy, Safety, and Resistance Mechanisms","volume":"143","author":"Lee","year":"2024","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"100929","DOI":"10.1016\/j.blre.2022.100929","article-title":"Current state and next-generation CAR-T cells in multiple myeloma","volume":"54","author":"Manier","year":"2022","journal-title":"Blood Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","article-title":"Proteasome Inhibitors in Cancer Therapy","volume":"14","author":"Manasanch","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Lu, Q., Yang, D., Li, H., Niu, T., and Tong, A. (2024). Multiple Myeloma: Signaling Pathways and Targeted Therapy. Mol. Biomed., 5.","DOI":"10.1186\/s43556-024-00188-w"},{"key":"ref_5","first-page":"199","article-title":"Proteasome Inhibitors for the Treatment of Multiple Myeloma","volume":"27","author":"Scalzulli","year":"2018","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Pinto, V., Bergantim, R., Caires, H.R., and Seca, H. (2020). Multiple Myeloma: Available Therapies and Causes of Drug Resistance. Cancers, 12.","DOI":"10.3390\/cancers12020407"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/bjh.15121","article-title":"Current Use of Monoclonal Antibodies in the Treatment of Multiple Myeloma","volume":"181","author":"Varga","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"60656","DOI":"10.18632\/oncotarget.19269","article-title":"Emerging Drugs and Combinations to Treat Multiple Myeloma","volume":"8","author":"Larocca","year":"2017","journal-title":"Oncotarget"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/s41375-020-0930-x","article-title":"Development of CAR-T Cell Therapies for Multiple Myeloma","volume":"34","author":"Gagelmann","year":"2020","journal-title":"Leukemia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1182\/blood.2023021221","article-title":"CAR T-Cell Therapy in Multiple Myeloma: Mission Accomplished?","volume":"143","author":"Rasche","year":"2024","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of Antigen Escape from BCMA- or GPRC5D-Targeted Immunotherapies in Multiple Myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s43018-024-00763-8","article-title":"Single-Cell Multiomic Dissection of Response and Resistance to Chimeric Antigen Receptor T Cells Against BCMA in Relapsed Multiple Myeloma","volume":"5","author":"Rade","year":"2024","journal-title":"Nat. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3322\/caac.21771","article-title":"Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma: A Comprehensive Review of Current Data and Implications for Clinical Practice","volume":"73","author":"Parikh","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41409-020-01023-w","article-title":"Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: Promise and Challenges","volume":"56","author":"Dhakal","year":"2021","journal-title":"Bone Marrow Transpl."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Wang, Z., Chen, C., Wang, L., Jia, Y., and Qin, Y. (2022). Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1050522"},{"key":"ref_16","first-page":"212","article-title":"From TCR Fundamental Research to Innovative Chimeric Antigen Receptor Design","volume":"24","author":"Minguet","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1186\/s13287-022-03163-w","article-title":"Recent Findings on Chimeric Antigen Receptor (CAR)-Engineered Immune Cell Therapy in Solid Tumors and Hematological Malignancies","volume":"13","author":"Keshavarz","year":"2022","journal-title":"Stem Cell Res. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Fujiwara, K., Kitaura, M., Tsunei, A., and Kusabuka, H. (2021). Structure of the Signal Transduction Domain in Second-Generation CAR Regulates the Input Efficiency of CAR Signals. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22052476"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/med.21818","article-title":"The Antigen-Binding Moiety in the Driver\u2019s Seat of CARs","volume":"42","author":"Hanssens","year":"2022","journal-title":"Med. Res. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Fujiwara, K., Tsunei, A., Kusabuka, H., and Ogaki, E. (2020). Hinge and Transmembrane Domains of Chimeric Antigen Receptor Regulate Receptor Expression and Signaling Threshold. Cells, 9.","DOI":"10.3390\/cells9051182"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41392-024-02096-5","article-title":"Chimeric Antigen Receptor with Novel Intracellular Modules Improves Antitumor Performance of T Cells","volume":"10","author":"Wang","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","article-title":"CAR-T and CAR-NK as Cellular Cancer Immunotherapy for Solid Tumors","volume":"21","author":"Peng","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Soldierer, M., Bister, A., Haist, C., and Thivakaran, A. (2022). Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.847008"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Lu, H., Zhao, X., Li, Z., Hu, Y., and Wang, H. (2021). From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.720501"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Ruppel, K.E., Fricke, S., K\u00f6hl, U., and Schmiedel, D. (2022). Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.822298"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40164-020-00190-2","article-title":"Engineering Better Chimeric Antigen Receptor T Cells","volume":"9","author":"Zhang","year":"2020","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/bjh.17186","article-title":"Chimeric Antigen Receptor (CAR) Natural Killer (NK)-Cell Therapy: Leveraging the Power of Innate Immunity","volume":"193","author":"Rafei","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","article-title":"CAR race to cancer immunotherapy: From CAR T, CAR NK to CAR macrophage therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Ram\u00edrez-Chac\u00f3n, A., Betriu-M\u00e9ndez, S., Bartol\u00f3-Ibars, A., Gonz\u00e1lez, A., Mart\u00ed, M., and Juan, M. (2022). Ligand-based CAR-T cell: Different strategies to drive T cells in future new treatments. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.932559"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Balkhi, S., Zuccolotto, G., Di Spirito, A., and Rosato, A. (2025). CAR-NK Cell Therapy: Promise and Challenges in Solid Tumors. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1574742"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Martarelli, N., Capurro, M., and Mansour, G. (2024). Artificial Intelligence-Powered Molecular Docking and Steered Molecular Dynamics for Accurate scFv Selection of Anti-CD30 Chimeric Antigen Receptors. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25137231"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Mao, R., Kong, W., and He, Y. (2022). The Affinity of Antigen-Binding Domain on the Antitumor Efficacy of CAR T Cells: Moderate Is Better. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1032403"},{"key":"ref_33","first-page":"e13683","article-title":"Comparison of Seven CD19 CAR Designs in Engineering NK Cells for Enhancing Anti-Tumour Activity","volume":"13","author":"Wang","year":"2024","journal-title":"Clin. Transl. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.omto.2022.10.011","article-title":"Gene-Edited and CAR-NK Cells: Opportunities and Challenges with Engineering of NK Cells for Immunotherapy","volume":"27","author":"Wu","year":"2024","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"145","DOI":"10.21147\/j.issn.1000-9604.2024.01.01","article-title":"Manufacturing CAR-NK Against Tumors: Who Is the Ideal Supplier?","volume":"36","author":"Guo","year":"2024","journal-title":"Chin. J. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1080\/08830185.2021.1984449","article-title":"The Immunologic Aspects of Cytokine Release Syndrome and Graft Versus Host Disease Following CAR T Cell Therapy","volume":"41","author":"Mansouri","year":"2022","journal-title":"Int. Rev. Immunol."},{"key":"ref_37","first-page":"63","article-title":"The Clinical Landscape of CAR NK Cells","volume":"14","author":"Christensen","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s40164-023-00402-5","article-title":"Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed\/refractory multiple myeloma through single-cell sequencing","volume":"12","author":"Li","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/ajh.26379","article-title":"Chimeric Antigen Receptor T-Cells, Bispecific Antibodies, and Antibody-Drug Conjugates for Multiple Myeloma: An Update","volume":"97","author":"Lakshman","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1182\/bloodadvances.2023010856","article-title":"Beyond BCMA: Newer Immune Targets in Myeloma","volume":"8","author":"Tan","year":"2024","journal-title":"Blood Adv."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Schavgoulidze, A., Cazaubiel, T., and Perrot, A. (2021). Multiple Myeloma: Heterogeneous in Every Way. Cancers, 13.","DOI":"10.3390\/cancers13061285"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Bartoszewska, E., Tota, M., Kisielewska, M., and Skowron, I. (2024). Overcoming Antigen Escape and T-Cell Exhaustion in CAR-T Therapy for Leukemia. Cells, 13.","DOI":"10.3390\/cells13181596"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13045-019-0813-7","article-title":"Multi-Antigen-Targeted Chimeric Antigen Receptor T Cells for Cancer Therapy","volume":"12","author":"Han","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Timmers, M., Roex, G., and Wang, Y. (2019). Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01613"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.omto.2023.07.001","article-title":"Development of a bicistronic anti-CD19\/CD20 CAR construct including abrogation of unexpected nucleic acid sequence deletions","volume":"30","author":"Lam","year":"2023","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ymthe.2024.11.028","article-title":"ARI0003: Co-Transduced CD19\/BCMA Dual-Targeting CAR-T Cells for the Treatment of Non-Hodgkin Lymphoma","volume":"33","author":"Bachiller","year":"2023","journal-title":"Mol. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1182\/bloodadvances.2024013586","article-title":"Dual-Targeting CAR T Cells for B-Cell Acute Lymphoblastic Leukemia and B-Cell Non-Hodgkin Lymphoma","volume":"9","author":"Roddie","year":"2025","journal-title":"Blood Adv."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Zhang, B., Wu, J., Jiang, H., and Zhou, M. (2025). Strategies to Overcome Antigen Heterogeneity in CAR-T Cell Therapy. Cells, 14.","DOI":"10.3390\/cells14050320"},{"key":"ref_49","first-page":"763","article-title":"Co-Opting Signalling Molecules Enables Logic-Gated Control of CAR T Cells","volume":"617","author":"Tousley","year":"2023","journal-title":"Nature"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e2312374120","DOI":"10.1073\/pnas.2312374120","article-title":"Dual-Inhibitory Domain iCARs Improve the Efficiency of the AND-NOT Gate CAR T Strategy","volume":"120","author":"Bangayan","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1042\/BST20170178","article-title":"Logic-Gated Approaches to Extend the Utility of Chimeric Antigen Receptor T-Cell Technology","volume":"46","author":"Ebert","year":"2018","journal-title":"Biochem. Soc. Trans."},{"key":"ref_52","first-page":"e008275","article-title":"CARs Are Sharpening Their Weapons","volume":"12","author":"Pievani","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Alabanza, L.M., Xiong, Y., Vu, B., Webster, B., Wu, D., Hu, P., Zhu, Z., Dropulic, B., Dash, P., and Schneider, D. (2022). Armored BCMA CAR T Cells Eliminate Multiple Myeloma and Are Resistant to the Suppressive Effects of TGF-\u03b2. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.832645"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e008261","DOI":"10.1136\/jitc-2023-008261","article-title":"Armored TGF\u03b2RIIDN ROR1-CAR T Cells Reject Solid Tumors and Resist Suppression by Constitutively-Expressed and Treatment-Induced TGF\u03b21","volume":"12","author":"Tran","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1158\/2326-6066.CIR-21-0536","article-title":"Superkine IL-2 and IL-33 Armored CAR T Cells Reshape the Tumor Microenvironment and Reduce Growth of Multiple Solid Tumors","volume":"10","author":"Brog","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"100739","DOI":"10.1016\/j.iotech.2024.100739","article-title":"Armoring chimeric antigen receptor (CAR) T cells as micropharmacies for cancer therapy","volume":"24","author":"Carcopino","year":"2024","journal-title":"Immunooncol Technol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Glienke, W., Dragon, A.C., Zimmermann, K., Martyniszyn-Eiben, A., Mertens, M., Abken, H., Rossig, C., Altvater, B., Aleksandrova, K., and Arseniev, L. (2022). GMP-Compliant Manufacturing of TRUCKs: CAR T Cells Targeting GD2 and Releasing Inducible IL-18. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.839783"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/imr.12125","article-title":"Of CARs and TRUCKs: Chimeric Antigen Receptor (CAR) T Cells Engineered with an Inducible Cytokine to Modulate the Tumor Stroma","volume":"257","author":"Chmielewski","year":"2014","journal-title":"Immunol. Rev."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Thomas, S., and Abken, H. (2023). CAR T Cell Therapy Becomes CHIC: \u201cCytokine Help Intensified CAR\u201d T Cells. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2022.1090959"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Silveira, C.R.F., Corveloni, A.C., and Caruso, S.R. (2022). Cytokines as an Important Player in the Context of CAR-T Cell Therapy for Cancer: Their Role in Tumor Immunomodulation, Manufacture, and Clinical Implications. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.947648"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/acg2.84","article-title":"TRUCKs, the Fourth-Generation CAR T Cells: Current Developments and Clinical Translation","volume":"3","author":"Chmielewski","year":"2020","journal-title":"Adv. Cell Gene Ther."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Zheng, Z., Li, S., Liu, M., Chen, C., Zhang, L., and Zhou, D. (2023). Fine-Tuning Through Generations: Advances in Structure and Production of CAR-T Therapy. Cancers, 15.","DOI":"10.3390\/cancers15133476"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"9577","DOI":"10.1021\/acs.jmedchem.0c02054","article-title":"Optimization of CAR-T Cell-Based Therapies Using Small-Molecule-Based Safety Switches","volume":"64","author":"Zheng","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e002755","DOI":"10.1136\/jitc-2021-002755","article-title":"Conditioned CAR-T Cells by Hypoxia-Inducible Transcription Amplification (HiTA) System Significantly Enhance Systemic Safety and Retain Antitumor Efficacy","volume":"9","author":"He","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e12109","DOI":"10.1002\/bmm2.12109","article-title":"Engineering Strategies to Mitigate Toxicities Associated with CAR-T Cell Therapy","volume":"3","author":"Wolter","year":"2025","journal-title":"BMEMat"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12943-025-02334-6","article-title":"Strategies to Overcome Tumor Relapse Caused by Antigen Escape After CAR T Therapy","volume":"24","author":"Lu","year":"2025","journal-title":"Mol. Cancer"},{"key":"ref_67","first-page":"1708","article-title":"Trogocytosis of CAR Molecule Regulates CAR-T Cell Dysfunction and Tumor Antigen Escape","volume":"14","author":"Zhai","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_68","first-page":"672","article-title":"T Cells Expressing CD5\/CD7 Bispecific Chimeric Antigen Receptors with Fully Human Heavy-Chain-Only Domains Mitigate Tumor Antigen Escape","volume":"23","author":"Dai","year":"2022","journal-title":"Nat. Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e176","DOI":"10.1002\/ctm2.176","article-title":"Long-Term Outcomes of Relapsed\/Refractory Double-Hit Lymphoma (R\/R DHL) Treated with CD19\/22 CAR T-Cell Cocktail Therapy","volume":"10","author":"Wei","year":"2020","journal-title":"Clin. Transl. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1182\/bloodadvances.2021004557","article-title":"Sequential Different B-Cell Antigen\u2013Targeted CAR T-Cell Therapy for Pediatric Refractory\/Relapsed Burkitt Lymphoma","volume":"6","author":"Liu","year":"2022","journal-title":"Blood Adv."},{"key":"ref_71","first-page":"445","article-title":"CAR-T Cell Combination Therapy: The Next Revolution in Cancer Treatment","volume":"14","author":"Tondok","year":"2022","journal-title":"J. Cancer Sci. Ther."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e008857","DOI":"10.1136\/jitc-2024-008857","article-title":"Combinational therapy of CAR T-cell and HDT\/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed\/refractory large B-cell lymphoma","volume":"12","author":"Liu","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13045-019-0758-x","article-title":"Target Selection for CAR-T Therapy","volume":"12","author":"Wei","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_74","first-page":"19","article-title":"A Review on Tumor Heterogeneity and Evolution in Multiple Myeloma: Pathological, Radiological, Molecular Genetics, and Clinical Integration","volume":"476","author":"Rasche","year":"2020","journal-title":"Virchows Arch."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Zhang, X., Zhang, H., Lan, H., Wu, J., and Xiao, Y. (2023). CAR-T Cell Therapy in Multiple Myeloma: Current Limitations and Potential Strategies. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1101495"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"476","DOI":"10.34172\/apb.2022.051","article-title":"CAR T Cells: Cancer Cell Surface Receptors are the Target for Cancer Therapy","volume":"12","author":"Shademan","year":"2021","journal-title":"Adv. Pharm. Bull."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Leow, C.C.Y., and Low, M.S.Y. (2021). Targeted Therapies for Multiple Myeloma. J. Pers. Med., 11.","DOI":"10.3390\/jpm11050334"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR Immune Cells: Design Principles, Resistance, and the Next Generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T Cell Therapy: Current Limitations and Potential Strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_80","unstructured":"(2025, May 15). Available online: https:\/\/clinicaltrials.gov\/study\/NCT03361748."},{"key":"ref_81","unstructured":"(2025, May 15). Available online: https:\/\/clinicaltrials.gov\/study\/NCT04162210."},{"key":"ref_82","unstructured":"(2025, May 15). Available online: https:\/\/clinicaltrials.gov\/study\/NCT04555551."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/bloodadvances.2024014982","article-title":"Anti-FcRL5 CAR-T exhibits anti-MM activity against EMM after progression of anti-BCMA and anti-GPRC5D CAR-T: A case report","volume":"9","author":"He","year":"2025","journal-title":"Blood Adv."},{"key":"ref_84","unstructured":"(2025, May 15). Available online: https:\/\/clinicaltrials.gov\/study\/NCT04351022."},{"key":"ref_85","unstructured":"(2025, May 15). Available online: https:\/\/clinicaltrials.gov\/study\/NCT03958656."},{"key":"ref_86","unstructured":"(2025, May 15). Available online: https:\/\/clinicaltrials.gov\/study\/NCT04430530."},{"key":"ref_87","unstructured":"(2025, May 15). Available online: https:\/\/clinicaltrials.gov\/study\/NCT02830724."},{"key":"ref_88","unstructured":"(2025, May 15). Available online: https:\/\/clinicaltrials.gov\/study\/NCT04623944."},{"key":"ref_89","unstructured":"(2025, May 15). Available online: https:\/\/clinicaltrials.gov\/study\/NCT02135406."},{"key":"ref_90","unstructured":"(2025, May 15). Available online: https:\/\/clinicaltrials.gov\/study\/NCT04318678."},{"key":"ref_91","unstructured":"(2025, May 15). Available online: https:\/\/clinicaltrials.gov\/study\/NCT02159495."},{"key":"ref_92","unstructured":"(2025, May 15). Available online: https:\/\/clinicaltrials.gov\/study\/NCT02623582."},{"key":"ref_93","unstructured":"(2025, May 15). Available online: https:\/\/clinicaltrials.gov\/study\/NCT04599543."},{"key":"ref_94","unstructured":"(2025, May 15). Available online: https:\/\/clinicaltrials.gov\/study\/NCT01716364."},{"key":"ref_95","first-page":"346","article-title":"A Phase I Study of Anti-BCMA CAR T Cell Therapy in Relapsed\/Refractory Multiple Myeloma and Plasma Cell Leukemia","volume":"10","author":"Li","year":"2021","journal-title":"Cancer Med."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Tannoury, M., Garnier, D., Susin, S.A., and Bauvois, B. (2022). Current Status of Novel Agents for the Treatment of B Cell Malignancies: What\u2019s Coming Next?. Cancers, 14.","DOI":"10.3390\/cancers14246026"},{"key":"ref_97","first-page":"5597","article-title":"Prospects for the Use of Antibody-Drug Conjugates in Cancer Therapy","volume":"94","author":"Makarova","year":"2025","journal-title":"Russ. Chem. Rev."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s13402-024-00984-0","article-title":"Next-generation BCMA-targeted Chimeric Antigen Receptor CARTemis-1: The Impact of Manufacturing Procedure on CAR T-cell Features","volume":"48","year":"2025","journal-title":"Cell. Oncol."},{"key":"ref_99","first-page":"9749363","article-title":"Development of Peptide-Based Vaccines for Cancer","volume":"2022","author":"Poh","year":"2022","journal-title":"J. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e010658","DOI":"10.1136\/jitc-2024-010658","article-title":"Expanding the CAR Toolbox with High Throughput Screening Strategies for CAR Domain Exploration: A Comprehensive Review","volume":"13","author":"Roex","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Utley, A., Lipchick, B., Lee, K.P., and Nikiforov, M.A. (2020). Targeting Multiple Myeloma Through the Biology of Long-lived Plasma Cells. Cancers, 12.","DOI":"10.3390\/cancers12082117"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.7150\/ijbs.108036","article-title":"From Molecular Design to Clinical Translation: Dual-targeted CAR-T Strategies in Cancer Immunotherapy","volume":"21","author":"Wang","year":"2025","journal-title":"Int. J. Biol. Sci."},{"key":"ref_103","first-page":"2432815","article-title":"Optimizing Treatment Sequencing in Multiple Myeloma: A Novel Model to Predict Survival Outcomes","volume":"143","author":"Petrucci","year":"2024","journal-title":"Acta Haematol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.4149\/neo_2022_220504N477","article-title":"CAR-T cells for the treatment of relapsed\/refractory multiple myeloma in 2022: Efficacy and toxicity","volume":"69","author":"Krejci","year":"2022","journal-title":"Neoplasma"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1158\/1078-0432.CCR-24-0378","article-title":"FDA Approval Summary: Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma","volume":"30","author":"Natrajan","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/17460441.2024.2319672","article-title":"The Preclinical Discovery and Clinical Development of Ciltacabtagene Autoleucel (Cilta-cel) for the Treatment of Multiple Myeloma","volume":"19","author":"Strassl","year":"2024","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Abebe, E.C., and Shiferaw, M.Y. (2022). Ciltacabtagene Autoleucel: The Second Anti-BCMA CAR T-Cell Therapeutic Armamentarium of Relapsed or Refractory Multiple Myeloma. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.991092"},{"key":"ref_108","first-page":"34","article-title":"EBMT-EHA 6th European CAR T-Cell Meeting 2024: Advancing Treatments and New Frontiers","volume":"20","author":"Holbro","year":"2024","journal-title":"Onco-Hema Heal. Times"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1038\/s41375-023-01883-3","article-title":"Preclinical Discovery and Initial Clinical Data of WVT078, a BCMA\u00d7 CD3 Bispecific Antibody","volume":"37","author":"Raab","year":"2023","journal-title":"Leukemia"},{"key":"ref_110","first-page":"1156","article-title":"Single-Cell Analysis of the Multiple Myeloma Microenvironment after \u03b3-Secretase Inhibition and CAR T-Cell Therapy","volume":"135","author":"Coffey","year":"2025","journal-title":"Blood"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Yu, T., Jiao, J.H., and Wu, M.F. (2025). CAR-T Cells in the Treatment of Multiple Myeloma: An Encouraging Cell Therapy. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1499590"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"155518","DOI":"10.1016\/j.prp.2024.155518","article-title":"Potential alternatives to \u03b1\u03b2-T cells to prevent graft-versus-host disease (GvHD) in allogeneic chimeric antigen receptor (CAR)-based cancer immunotherapy: A comprehensive review","volume":"262","author":"Tang","year":"2024","journal-title":"Pathol Res Pract."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Lonez, C., and Breman, E. (2024). Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met?. Cells, 13.","DOI":"10.3390\/cells13020146"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s43440-025-00715-8","article-title":"Polypharmacology: New Drugs in 2023\u20132024","volume":"77","author":"Ryszkiewicz","year":"2025","journal-title":"Pharmacol. Rep."},{"key":"ref_115","first-page":"767","article-title":"GPRC5D as a Novel Target for the Treatment of Multiple Myeloma: A Narrative Review","volume":"38","year":"2024","journal-title":"Leukemia"},{"key":"ref_116","first-page":"1156","article-title":"Targeting GPRC5D for Multiple Myeloma Therapy","volume":"38","author":"Zhou","year":"2024","journal-title":"Leukemia"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"70764","DOI":"10.1002\/cam4.70764","article-title":"Application of GPRC5D Targeting Therapy in Relapsed Refractory Multiple Myeloma","volume":"14","author":"Yan","year":"2025","journal-title":"Cancer Med."},{"key":"ref_118","first-page":"203","article-title":"Current Progress of CAR-T-Cell Therapy for Patients with Multiple Myeloma","volume":"109","author":"Nakashima","year":"2024","journal-title":"Int. J. Hematol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.2174\/0118715206350342241224073809","article-title":"A Systematic Review and Meta-analysis on the Safety and Efficacy of CAR T Cell Therapy Targeting GPRC5D in Patients with Multiple Myeloma: A New Insight in Cancer Immunotherapy","volume":"25","author":"Mahalleh","year":"2025","journal-title":"Anticancer Agents Med. Chem."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/S2352-3026(22)00372-6","article-title":"GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): A first-in-human, single-center, single-arm, phase 1 trial","volume":"10","author":"Zhang","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e365","DOI":"10.1016\/S2352-3026(25)00048-1","article-title":"Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: A single-centre, single-arm, phase 2 trial","volume":"12","author":"Xia","year":"2025","journal-title":"Lancet Haematol."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Vera-Cruz, S., Jornet Culubret, M., Konetzki, V., and Alb, M. (2024). Cellular Therapies for Multiple Myeloma: Engineering Hope. Cancers, 16.","DOI":"10.3390\/cancers16223867"},{"key":"ref_123","first-page":"A284","article-title":"A GPRC5D and BCMA bispecific CAR-T product demonstrated dual antigen targeting capability and efficacy against multiple myeloma cells bearing BCMA","volume":"12","author":"Chang","year":"2024","journal-title":"J Immunother Cancer."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1158\/1538-7445.AM2025-3183","article-title":"Abstract 3183: GPRC5D and BCMA Bi-Specific CAR-T: Optimized CAR Design to Mitigate Antigen Escape and Elicit Deep and Durable Response in Heterogeneous Multiple Myeloma","volume":"85","author":"Zhou","year":"2025","journal-title":"Cancer Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/1750743X.2025.2461987","article-title":"Allogeneic Chimeric Antigen Receptors (CARs) as an \u201cOff-the-Shelf\u201d Therapy in Multiple Myeloma","volume":"17","author":"Carlson","year":"2025","journal-title":"Immunotherapy"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"6122","DOI":"10.1158\/1538-7445.AM2025-6122","article-title":"Abstract 6122: Off-the-Shelf BCMA\/GPRC5D Dual Targeted CAR-NK Cell Therapy Combined with Daratumumab in Treating Multiple Myeloma","volume":"85","author":"Wang","year":"2025","journal-title":"Cancer Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41392-023-01702-2","article-title":"Fc Receptor-Like 5 (FCRL5)-Directed CAR-T Cells Exhibit Antitumor Activity Against Multiple Myeloma","volume":"9","author":"Yu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.1038\/s41467-023-39395-4","article-title":"Chimeric Antigen Receptor T Cells Targeting FcRH5 Provide Robust Tumour-Specific Responses in Murine Xenograft Models of Multiple Myeloma","volume":"14","author":"Jiang","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Miller, K.C., Hashmi, H., and Rajeeve, S. (2024). Beyond BCMA: The Next Wave of CAR T Cell Therapy in Multiple Myeloma. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1398902"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13045-023-01489-3","article-title":"Bispecific Antibodies Targeting BCMA, GPRC5D, and FcRH5 for Multiple Myeloma Therapy: Latest Updates from ASCO 2023 Annual Meeting","volume":"16","author":"Zhao","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1159\/000543265","article-title":"Novel Approaches of Cellular Therapy in Multiple Myeloma: Focus on Chimeric Antigen Receptor T-Cells","volume":"148","author":"Narra","year":"2024","journal-title":"Acta Haematol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1182\/blood-2020-136985","article-title":"Initial Clinical Activity and Safety of BFCR4350A, a FcRH5\/CD3 T-cell-Engaging Bispecific Antibody, in Relapsed\/Refractory Multiple Myeloma","volume":"136","author":"Cohen","year":"2020","journal-title":"Blood"},{"key":"ref_133","first-page":"267","article-title":"Bispecific Antibody Constructs in Multiple Myeloma: Affinities, Dosing Strategies, and Future Perspectives","volume":"24","author":"Waldschmidt","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/jha2.729","article-title":"T-Cell Redirecting Bispecific Antibodies in Multiple Myeloma: Current Landscape and Future Directions","volume":"4","year":"2023","journal-title":"EJHaem"},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"He, Y., Vlaming, M., van Meerten, T., and Bremer, E. (2022). The Implementation of TNFRSF Co-stimulatory Domains in CAR-T Cells for Optimal Functional Activity. Cancers, 14.","DOI":"10.3390\/cancers14020299"},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Honikel, M.M., and Olejniczak, S.H. (2022). Co-Stimulatory Receptor Signaling in CAR-T Cells. Biomolecules, 12.","DOI":"10.3390\/biom12091303"},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Fu, B., Liu, R., Gao, G., Lin, Z., and He, A. (2024). Mechanisms and Salvage Treatments in Patients with Multiple Myeloma Relapsed Post-BCMA CAR-T Cell Therapy. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1433774"},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Mishra, A.K., Gupta, A., Dagar, G., Das, D., Chakraborty, A., Haque, S., Prasad, C.P., Singh, A., Bhat, A.A., and Macha, M.A. (2023). CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond. Vaccines, 11.","DOI":"10.3390\/vaccines11111721"},{"key":"ref_139","first-page":"102424","article-title":"The Calcium Signaling Enzyme CD38\u2014A Paradigm for Membrane Topology Defining Distinct Protein Functions","volume":"99","author":"Lee","year":"2022","journal-title":"Cell Calcium"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1136\/gutjnl-2024-331914","article-title":"Heavy Arch: From Inflammatory Bowel Diseases to Metabolic Disorders","volume":"73","author":"Adolph","year":"2024","journal-title":"Gut"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1073\/pnas.1413493112","article-title":"Seminal CD38 Is a Pivotal Regulator for Fetomaternal Tolerance","volume":"112","author":"Kim","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s40487-025-00333-7","article-title":"Cost-Effectiveness of Elranatamab Versus Current Therapies for the Management of Patients with Triple-Class Exposed, Relapsed and Refractory Multiple Myeloma, Including Other Bispecific and Physician\u2019s Choice of Treatment in Spain","volume":"13","author":"Encinas","year":"2025","journal-title":"Oncol. Ther."},{"key":"ref_143","first-page":"273","article-title":"CD38-Directed Therapies for Management of Multiple Myeloma","volume":"13","author":"Hashmi","year":"2021","journal-title":"Immunotherapy"},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Guerrero, E., and Sierro-Mart\u00ednez, B. (2020). Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.01128"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/20406207251326802","article-title":"Recent Advances of CAR-T Cells in Acute Myeloid Leukemia","volume":"16","author":"Deng","year":"2025","journal-title":"Ther. Adv. Hematol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"e006325","DOI":"10.1136\/jitc-2022-006325","article-title":"All-Trans Retinoic Acid Improves NSD2-Mediated RAR\u03b1 Phase Separation and Efficacy of Anti-CD38 CAR T-Cell Therapy in Multiple Myeloma","volume":"11","author":"Peng","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_147","first-page":"210","article-title":"CAR T Therapies in Multiple Myeloma: Unleashing the Future","volume":"5","author":"Sheykhhasan","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1158\/2767-9764.CRC-23-0434","article-title":"Ex Vivo Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies","volume":"4","author":"Keller","year":"2024","journal-title":"Cancer Res Commun."},{"key":"ref_149","first-page":"667","article-title":"A Bispecific CAR-T Cell Therapy Targeting BCMA and CD38 in Relapsed or Refractory Multiple Myeloma","volume":"35","author":"Mei","year":"2021","journal-title":"Leukemia"},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"De Novellis, D., Fontana, R., Giudice, V., and Serio, B. (2022). Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24010645"},{"key":"ref_151","first-page":"2681","article-title":"European Myeloma Network Perspective on CAR T-Cell Therapies for Multiple Myeloma","volume":"39","author":"Bruno","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_152","first-page":"131","article-title":"Anti-CD38 and Anti-SLAMF7: The Future of Myeloma Immunotherapy","volume":"132","author":"Zamagni","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.critrevonc.2013.04.003","article-title":"CS1, a SLAM Family Receptor Involved in Immune Regulation, Is a Therapeutic Target in Multiple Myeloma","volume":"88","author":"Veillette","year":"2013","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/17534259251326700","article-title":"Emerging Roles of SLAMF7 in Immune Cells and Related Diseases","volume":"31","author":"Zhang","year":"2025","journal-title":"Innate Immun."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1182\/blood-2017-04-778423","article-title":"SLAMF7-CAR T Cells Eliminate Myeloma and Confer Selective Fratricide of SLAMF7+ Normal Lymphocytes","volume":"130","author":"Gogishvili","year":"2017","journal-title":"Blood"},{"key":"ref_156","first-page":"133","article-title":"The Potential Role of CAR-T in Multiple Myeloma Treatment: A Review","volume":"12","author":"Kostelecka","year":"2024","journal-title":"Cent. Eur. J. Oncol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s11010-022-04568-0","article-title":"Challenges of Chimeric Antigen Receptor-T\/Natural Killer Cell Therapy in the Treatment of Solid Tumors: Focus on Colorectal Cancer and Evaluation of Combination Therapies","volume":"478","author":"Wang","year":"2023","journal-title":"Mol. Cell. Biochem."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/s41434-021-00254-w","article-title":"CARAMBA: A First-in-Human Clinical Trial with SLAMF7 CAR-T Cells Prepared by Virus-Free Sleeping Beauty Gene Transfer to Treat Multiple Myeloma","volume":"28","author":"Prommersberger","year":"2021","journal-title":"Gene Ther."},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Chu, E., Wu, J., Kang, S.S., and Kang, Y. (2023). SLAMF7 as a Promising Immunotherapeutic Target in Multiple Myeloma Treatments. Curr. Oncol., 30.","DOI":"10.3390\/curroncol30090573"},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Hassan, N., Efing, J., Kiesel, L., Bendas, G., and G\u00f6tte, M. (2023). The Tissue Factor Pathway in Cancer: Overview and Role of Heparan Sulfate Proteoglycans. Cancers, 15.","DOI":"10.3390\/cancers15051524"},{"key":"ref_161","first-page":"158","article-title":"CAR-T Cells in Multiple Myeloma: Current Status","volume":"13","author":"Steiner","year":"2020","journal-title":"Memo\u2014Mag. Eur. Med. Oncol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"e446","DOI":"10.1016\/S2352-3026(21)00057-0","article-title":"CAR T-Cell Therapy for Multiple Myeloma: State of the Art and Prospects","volume":"8","author":"Usmani","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"33","DOI":"10.21037\/sci-2020-029","article-title":"Novel Progresses of Chimeric Antigen Receptor (CAR) T Cell Therapy in Multiple Myeloma","volume":"8","author":"Ding","year":"2021","journal-title":"Stem Cell Investig."},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Riccardi, F., Tangredi, C., Dal Bo, M., and Toffoli, G. (2024). Targeted Therapy for Multiple Myeloma: An Overview on CD138-Based Strategies. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1370854"},{"key":"ref_165","first-page":"1234","article-title":"Targeting High-Risk Multiple Myeloma Genotypes with Optimized Anti-CD70 CAR-T Cells","volume":"15","author":"Kasap","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1182\/blood-2023-182578","article-title":"Discovery and Development of CD70 as a Cellular Therapy Target in High-Risk Multiple Myeloma","volume":"142","author":"Kasap","year":"2023","journal-title":"Blood"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1182\/blood.2020008221","article-title":"CD70-Specific CAR T Cells Have Potent Activity Against Acute Myeloid Leukemia Without HSC Toxicity","volume":"138","author":"Sauer","year":"2021","journal-title":"Blood"},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Wu, G., Guo, S., Luo, Q., Wang, X., Deng, W., Ouyang, G., Pu, J.J., Lei, W., and Qian, W. (2023). Preclinical Evaluation of CD70-Specific CAR T Cells Targeting Acute Myeloid Leukemia. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1093750"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"TPS2676","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS2676","article-title":"A Phase 1\/2, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9\u2013Engineered T Cells (CTX131) in Adult Patients with Relapsed or Refractory Solid Tumors","volume":"42","author":"Pal","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_170","first-page":"110","article-title":"Safety and Activity of CTX130, a CD70-Targeted Allogeneic CRISPR-Cas9-Engineered CAR T-Cell Therapy, in Patients with Relapsed or Refractory T-Cell Malignancies (COBALT-LYM): A Single-Arm, Open-Label, Phase 1, Dose-Escalation Study","volume":"25","author":"Iyer","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1182\/blood-2023-190612","article-title":"CD70 CAR NK Cells in the Treatment of Multiple Myeloma","volume":"142","author":"Lin","year":"2023","journal-title":"Blood"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/bloodadvances.2023012202","article-title":"CD70-Specific CAR NK Cells Expressing IL-15 for the Treatment of CD19-Negative B-Cell Malignancy","volume":"8","author":"Guo","year":"2024","journal-title":"Blood Adv."},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Testa, U., Castelli, G., and Pelosi, E. (2025). Emerging Role of Chimeric Antigen Receptor-Natural Killer Cells for the Treatment of Hematologic Malignancies. Cancers, 17.","DOI":"10.3390\/cancers17091454"},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Olejarz, W., and Basak, G. (2023). Emerging Therapeutic Targets and Drug Resistance Mechanisms in Immunotherapy of Hematological Malignancies. Cancers, 15.","DOI":"10.3390\/cancers15245765"},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Boneva, E., Shivarov, V., and Ivanova, M. (2025). A Concise Review of the Role of the NKG2D Receptor and Its Ligands in Cancer. Immuno, 5.","DOI":"10.3390\/immuno5010009"},{"key":"ref_176","doi-asserted-by":"crossref","unstructured":"Tan, G., Spillane, K.M., and Maher, J. (2023). The Role and Regulation of the NKG2D\/NKG2D Ligand System in Cancer. Biology, 12.","DOI":"10.3390\/biology12081079"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/cmi.2017.161","article-title":"Functions of NKG2D in CD8+ T Cells: An Opportunity for Immunotherapy","volume":"15","author":"Prajapati","year":"2018","journal-title":"Cell. Mol. Immunol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"e306","DOI":"10.1038\/bcj.2015.32","article-title":"The Cellular Immune System in Myelomagenesis: NK Cells and T Cells in the Development of Myeloma and Their Uses in Immunotherapies","volume":"5","author":"Dosani","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_179","doi-asserted-by":"crossref","unstructured":"Liu, J., Dai, K., Saliu, M.A., Salisu, M.D., Gan, J., Afolabi, L.O., Yan, D., Zhang, G., Liu, M., and Wan, X. (2025). Sodium valproate enhances efficacy of NKG2D CAR-T cells against glioblastoma. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1519777"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41408-024-00997-w","article-title":"Bispecific Antibodies and CAR-T Cells: Dueling Immunotherapies for Large B-Cell Lymphomas","volume":"14","author":"Trabolsi","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Dada, R. (2023). Redefining Precision Management of R\/R Large B-Cell Lymphoma: Novel Antibodies Take on CART and BMT in the Quest for Future Treatment Strategies. Cells, 12.","DOI":"10.3390\/cells12141858"},{"key":"ref_182","first-page":"106567","article-title":"Chimeric Antigen Receptor T Cell Therapy in Oncology\u2013Pipeline at a Glance: Analysis of the ClinicalTrials.gov Database","volume":"104","year":"2021","journal-title":"Leuk. Res."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-021-00469-5","article-title":"CAR T-Cell Therapy in Multiple Myeloma: More Room for Improvement","volume":"11","author":"Teoh","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jtct.2023.04.007","article-title":"Mechanisms of Resistance and Treatment of Relapse After CAR T-Cell Therapy for Large B-Cell Lymphoma and Multiple Myeloma","volume":"29","author":"Rejeski","year":"2023","journal-title":"Transplant. Cell Ther."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/QCO.0000000000001022","article-title":"Hematopoietic Stem Cell Transplantation and Cellular Therapy in Persons Living with HIV","volume":"37","author":"Rubinstein","year":"2024","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.15537\/smj.2024.45.10.20240330","article-title":"CAR T-Cell Therapy in Acute Myeloid Leukemia","volume":"45","author":"Almotiri","year":"2024","journal-title":"Saudi Med. J."},{"key":"ref_187","doi-asserted-by":"crossref","unstructured":"Salehi-Shadkami, H., Sedghi, M., and Tavoosi, S. (2024). Effective Targeting of CD19 Positive Primary B-ALL Cells Using CAR-NK Cells Generated with mRNA-LNPs. bioRxiv.","DOI":"10.1101\/2024.11.21.624707"},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Kang, L., Zhang, J., Li, M., Xu, N., Qi, W., Tan, J., Lou, X., Yu, Z., Sun, J., and Wang, Z. (2020). Characterization of Novel Dual Tandem CD19\/BCMA Chimeric Antigen Receptor T Cells to Potentially Treat Multiple Myeloma. Biomark. Res., 8.","DOI":"10.1186\/s40364-020-00192-6"},{"key":"ref_189","first-page":"25","article-title":"Clinical Results of a Multicenter Study of the First-in-Human Dual BCMA and CD19 Targeted Novel Platform Fast CAR-T Cell Therapy for Patients with Relapsed\/Refractory Multiple Myeloma","volume":"136","author":"Jiang","year":"2020","journal-title":"Blood"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"e84060bf","DOI":"10.1097\/01.HS9.0000970380.84060.bf","article-title":"P869: Updated Results of a Phase I, Open-Label Study of BCMA\/CD19 Dual-Targeting FasTCAR-T GC012F for Patients with Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"7","author":"Du","year":"2023","journal-title":"HemaSphere"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/14712598.2024.2443093","article-title":"Advances in CD19-Targeting CAR-T Cell Therapies for Multiple Myeloma","volume":"25","author":"Steinhardt","year":"2025","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"Xu, H., Guan, C., Xu, P., Zhou, D., Xu, Y., Chen, B., and Bai, H. (2024). Clinical Efficacy and Safety of Combined Anti-BCMA and Anti-CD19 CAR-T Cell Therapy for Relapsed\/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1355643"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/ajh.26486","article-title":"Anti-BCMA CAR T Cell Therapy Followed by Lenalidomide Maintenance after Autologous Stem-Cell Transplantation for High-Risk Newly Diagnosed Multiple Myeloma","volume":"97","author":"Shi","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41375-019-0669-4","article-title":"Anti-BCMA CAR T-Cell Therapy in Multiple Myeloma: Can We Do Better?","volume":"34","author":"Raje","year":"2020","journal-title":"Leukemia"},{"key":"ref_195","first-page":"1234","article-title":"Bispecific CAR T Cell Therapy Targeting BCMA and CD19 in Relapsed\/Refractory Multiple Myeloma: A Phase I\/II Trial","volume":"15","author":"Shi","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_196","doi-asserted-by":"crossref","unstructured":"Pinti, M., Gibellini, L., Lo Tartaro, D., De Biasi, S., Nasi, M., Borella, R., Fidanza, L., Neroni, A., Troiano, L., and Franceschi, C. (2023). A Comprehensive Analysis of Cytokine Network in Centenarians. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032719"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00262-024-03913-0","article-title":"Targeting BCMA in Multiple Myeloma: Designs, Challenges, and Future Directions","volume":"74","author":"Hu","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1158\/1538-7445.AM2022-556","article-title":"Abstract 556: Novel anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma","volume":"82","author":"Larson","year":"2022","journal-title":"Cancer Res."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s12185-022-03365-1","article-title":"Novel Immunotherapies in Multiple Myeloma","volume":"115","author":"Ohmine","year":"2022","journal-title":"Int. J. Hematol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"7509","DOI":"10.1038\/s41467-023-43416-7","article-title":"Anti-TACI Single and Dual-Targeting CAR T Cells Overcome BCMA Antigen Loss in Multiple Myeloma","volume":"14","author":"Larson","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.coi.2021.06.012","article-title":"Keeping Up with the Stress of Antibody Production: BAFF and APRIL Maintain Memory Plasma Cells","volume":"71","author":"Cornelis","year":"2021","journal-title":"Curr. Opin. Immunol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"e2404309121","DOI":"10.1073\/pnas.2404309121","article-title":"Unique and Redundant Roles of Mouse BCMA, TACI, BAFF, APRIL, and IL-6 in Supporting Antibody-Producing Cells in Different Tissues","volume":"121","author":"Eslami","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-Cell Maturation Antigen (BCMA) in Multiple Myeloma: Rationale for Targeting and Current Therapeutic Approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"key":"ref_204","doi-asserted-by":"crossref","unstructured":"Camviel, N., Wolf, B., Croce, G., and Gfeller, D. (2022). Both APRIL and Antibody-Fragment-Based CAR T Cells for Myeloma Induce BCMA Downmodulation by Trogocytosis and Internalization. Front. Immunol., 13.","DOI":"10.1136\/jitc-2022-005091"},{"key":"ref_205","doi-asserted-by":"crossref","unstructured":"Ullah, M., and Mackay, F. (2023). The BAFF-APRIL System in Cancer. Cancers, 15.","DOI":"10.3390\/cancers15061791"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1182\/bloodadvances.2019000703","article-title":"Rational Design of a Trimeric APRIL-Based CAR-Binding Domain Enables Efficient Targeting of Multiple Myeloma","volume":"3","author":"Schmidts","year":"2019","journal-title":"Blood Adv."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/14728222.2019.1586886","article-title":"Tumor Necrosis Factor Receptor-2 (TNFR2): An Overview of an Emerging Drug Target","volume":"23","author":"Medler","year":"2019","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.7150\/ijbs.108803","article-title":"Unraveling the Breast Cancer Tumor Microenvironment: Crucial Factors Influencing Natural Killer Cell Function and Therapeutic Strategies","volume":"21","author":"Li","year":"2025","journal-title":"Int. J. Biol. Sci."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2147\/ITT.S255224","article-title":"TNFR2: Role in Cancer Immunology and Immunotherapy","volume":"10","author":"Yang","year":"2021","journal-title":"ImmunoTargets Ther."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1186\/s12967-024-05620-x","article-title":"Targeting TNFR2 for Cancer Immunotherapy: Recent Advances and Future Directions","volume":"22","author":"Li","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_211","doi-asserted-by":"crossref","unstructured":"Moatti, A., and Cohen, J.L. (2021). The TNF-\u03b1\/TNFR2 Pathway: Targeting a Brake to Release the Anti-Tumor Immune Response. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.725473"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s13577-024-01083-w","article-title":"Immunosuppressive Regulatory Cells in Cancer Immunotherapy: Restrain or Modulate?","volume":"37","author":"Wu","year":"2024","journal-title":"Hum. Cell"},{"key":"ref_213","doi-asserted-by":"crossref","unstructured":"Ba, H., Dai, Z., Zhang, Z., Zhang, P., Yin, B., Wang, J., Li, Z., and Zhou, X. (2023). Antitumor Effect of CAR-T Cells Targeting Transmembrane Tumor Necrosis Factor Alpha Combined with PD-1 mAb on Breast Cancers. Front. Immunol., 11.","DOI":"10.1136\/jitc-2021-003837"},{"key":"ref_214","doi-asserted-by":"crossref","unstructured":"Takahashi, H., Yoshimatsu, G., and Faustman, D.L. (2022). The Roles of TNFR2 Signaling in Cancer Cells and the Tumor Microenvironment and the Potency of TNFR2 Targeted Therapy. Cells, 11.","DOI":"10.3390\/cells11121952"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"eaaz3866","DOI":"10.1126\/scitranslmed.aaz3866","article-title":"Functional Effects of Chimeric Antigen Receptor Co-Receptor Signaling Domains in Human Regulatory T Cells","volume":"12","author":"Dawson","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_216","doi-asserted-by":"crossref","unstructured":"D\u2019Accardo, C., Porcelli, G., Mangiapane, L.R., Modica, C., Pantina, V.D., Roozafzay, N., Di Franco, S., Gaggianesi, M., Veschi, V., and Lo Iacono, M. (2022). Cancer cell targeting by CAR-T cells: A matter of stemness. Front. Mol. Med., 2.","DOI":"10.3389\/fmmed.2022.1055028"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1182\/blood-2013-04-493361","article-title":"CD44v6-Targeted T Cells Mediate Potent Antitumor Effects Against Acute Myeloid Leukemia and Multiple Myeloma","volume":"122","author":"Casucci","year":"2013","journal-title":"Blood"},{"key":"ref_218","doi-asserted-by":"crossref","unstructured":"Wang, Z., Zhao, K., Hackert, T., and Z\u00f6ller, M. (2018). CD44\/CD44v6: A Reliable Companion in Cancer-Initiating Cell Maintenance and Tumor Progression. Front. Cell Dev. Biol., 6.","DOI":"10.3389\/fcell.2018.00097"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.clml.2021.06.003","article-title":"Emerging Targets and Cellular Therapy for Relapsed Refractory Multiple Myeloma: A Systematic Review","volume":"21","author":"George","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"311","DOI":"10.14740\/wjon1521","article-title":"Extramedullary Multiple Myeloma: A Patient-Focused Review of the Pathogenesis of Bone Marrow Escape","volume":"13","author":"Gupta","year":"2022","journal-title":"World J. Oncol."},{"key":"ref_221","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez-Lobato, L.G., Ganzetti, M., Fern\u00e1ndez de Larrea, C., Hudecek, M., Einsele, H., and Danhof, S. (2020). CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.01243"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"eadj6251","DOI":"10.1126\/sciadv.adj6251","article-title":"Enhancing the Safety of CAR-T Cell Therapy: Synthetic Genetic Switch for Spatiotemporal Control","volume":"10","author":"Lu","year":"2024","journal-title":"Sci. Adv."},{"key":"ref_223","first-page":"A250","article-title":"Harnessing anti-CD44v6 CAR-NK cells for effective head and neck squamous cell carcinoma treatment","volume":"12","author":"Ciulean","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_224","doi-asserted-by":"crossref","unstructured":"Ciulean, I.S., Fischer, J., Quaiser, A., Bach, C., Abken, H., Tretbar, U.S., Fricke, S., Koehl, U., Schmiedel, D., and Grunwald, T. (2023). CD44v6 Specific CAR-NK Cells for Targeted Immunotherapy of Head and Neck Squamous Cell Carcinoma. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1290488"},{"key":"ref_225","doi-asserted-by":"crossref","unstructured":"Porcellini, S., Asperti, C., Corna, S., Cicoria, E., Valtolina, V., Stornaiuolo, A., Valentinis, B., Bordignon, C., and Traversari, C. (2020). CAR T Cells Redirected to CD44v6 Control Tumor Growth in Lung and Ovary Adenocarcinoma Bearing Mice. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00099"},{"key":"ref_226","doi-asserted-by":"crossref","unstructured":"Lodewijk, I., Due\u00f1as, M., and Paramio, J.M. (2023). CD44v6, STn & O-GD2: Promising Tumor Associated Antigens Paving the Way for New Targeted Cancer Therapies. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1272681"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1182\/blood-2018-99-117974","article-title":"Phase I\u2013IIa Clinical Trial to Assess Safety and Efficacy of MLM-CAR44.1, a CD44v6 Directed CAR-T in Relapsed\/Refractory Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM)","volume":"132","author":"Carrabba","year":"2018","journal-title":"Blood"},{"key":"ref_228","doi-asserted-by":"crossref","unstructured":"Van der Schans, J.J., Van de Donk, N.W.C.J., and Mutis, T. (2020). Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.01362"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1038\/nm.4431","article-title":"The Activated Conformation of Integrin \u03b27 Is a Novel Multiple Myeloma\u2013Specific Target for CAR T Cell Therapy","volume":"23","author":"Hosen","year":"2017","journal-title":"Nat. Med."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1038\/mt.2013.154","article-title":"Persistence and Efficacy of Second Generation CAR T Cell Against the LeY Antigen in Acute Myeloid Leukemia","volume":"21","author":"Ritchie","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_231","first-page":"208","article-title":"New Targets for CAR T Therapy in Hematologic Malignancies","volume":"58","author":"Savani","year":"2021","journal-title":"Semin. Hematol."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1158\/1541-7786.MCR-21-0828","article-title":"Redefining CD56 as a Biomarker and Therapeutic Target in Multiple Myeloma","volume":"20","author":"Cottini","year":"2022","journal-title":"Mol. Cancer Res."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"153567","DOI":"10.1016\/j.prp.2021.153567","article-title":"CD56 Expression in Multiple Myeloma: Correlation with Poor Prognostic Markers but No Effect on Outcome","volume":"225","author":"Koumpis","year":"2021","journal-title":"Pathol. Res. Pract."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1080\/1042819031000149377","article-title":"Prognostic Significance of Surface Markers Expressed in Multiple Myeloma: CD56 and Other Antigens","volume":"45","author":"Sahara","year":"2004","journal-title":"Leuk. Lymphoma"},{"key":"ref_235","first-page":"62","article-title":"Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma","volume":"112","author":"Hosen","year":"2020","journal-title":"Int. J. Hematol."},{"key":"ref_236","doi-asserted-by":"crossref","unstructured":"Uckun, F.M. (2021). Dual targeting of multiple myeloma stem cells and myeloid-derived suppressor cells for treatment of chemotherapy-resistant multiple myeloma. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.760382"},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"8975","DOI":"10.3390\/curroncol29110705","article-title":"Treating multiple myeloma in the context of the bone marrow microenvironment","volume":"29","author":"Ho","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_238","doi-asserted-by":"crossref","unstructured":"Testa, U., Pelosi, E., and Castelli, G. (2019). CD123 as a therapeutic target in the treatment of hematological malignancies. Cancers, 11.","DOI":"10.3390\/cancers11091358"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s13045-022-01376-3","article-title":"Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia","volume":"15","author":"Caruso","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/gt.2010.21","article-title":"Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen","volume":"17","author":"Peinert","year":"2010","journal-title":"Gene Ther."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1186\/s13287-021-02420-8","article-title":"Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s13045-017-0535-7","article-title":"Clinical trials of CAR-T cells in China","volume":"10","author":"Liu","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_243","doi-asserted-by":"crossref","unstructured":"Smith, L., and Di Stasi, A. (2022). Safety switches used for cellular therapies. Gene and Cellular Immunotherapy for Cancer, Springer.","DOI":"10.1007\/978-3-030-87849-8_6"},{"key":"ref_244","doi-asserted-by":"crossref","unstructured":"Gargett, T., and Brown, M.P. (2014). The inducible caspase-9 suicide gene system as a \u201csafety switch\u201d to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Front. Pharmacol., 5.","DOI":"10.3389\/fphar.2014.00235"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/13\/6051\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:57:42Z","timestamp":1760032662000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/13\/6051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,24]]},"references-count":244,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["ijms26136051"],"URL":"https:\/\/doi.org\/10.3390\/ijms26136051","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,24]]}}}